RxDoctor Payments Data

Cynthia Rogers, NP

Nurse Practitioner · Huntsville, ALNPI 1295075455

Payments from drug & device makers

$7,174in general payments, 2019–2025

Across 376 payments — averaging $19.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Madrigal Pharmaceuticals$528
  • Johnson & Johnson$448
  • Regeneron Healthcare Solutions, Inc.$265
  • Gilead$248
  • plus $2K from 13 others

What the payments were for

  • Food & beverage$7,07499%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,174 in reported general payments places this provider in the 95th percentile of 1,505 nurse practitioner providers in Alabama.

See all nurse practitioner providers in Alabama

Medicare billing

Part B allowed, 2024
$61,186
Medicare patients
533
Services billed
963

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RelistorMethylnaltrexone Bromide13$30,455
LinzessLinaclotide14$16,444
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates197$12,525
Mesalamine ErMesalamine12$6,190
MovantikNaloxegol Oxalate14$5,503
Dexlansoprazole DrDexlansoprazole12$4,245
Esomeprazole Magnesium28$3,722
Omeprazole238$3,418
Famotidine157$2,115
Lansoprazole18$1,609
Pantoprazole Sodium96$1,302
Rabeprazole Sodium19$820
Ondansetron Hcl22$621
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg18$435
Sulfasalazine11$360

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$1,444$30,45513 claims
AbbVieLinzess$2,711$16,44414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,505 nurse practitioner providers in Alabama.

Other nurse practitioner in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →